康希诺生物

To provide innovative, high-quality, and affordable vaccines.

We conduct in-depth analyses of scientific principles, technological platforms, and global strategies to expedite medical research and development. By empowering medical professionals and industry partners, we adhere to the professional academic and customer demand-oriented marketing concept. We are committed to responsible marketing practices, providing comprehensive service guarantees for our customers, and significantly enhancing the user experience.

Access to Health Care: As a global vaccine supplier based in China, CanSinoBIO always adheres to the concept of jointly building a health community with a shared future. While pursuing innovative development of our products and technology, we cooperate with international organizations, governments, and enterprises to form a strong driving force for promoting the vaccine accessibility and contributing to human health.

Accessible Product and Technology: We conduct exchanges and cooperation with governments and local enterprises in developing countries, accelerates technological export through technology transfer, and promotes the popularization of technology in R&D, manufacturing, and other aspects in developing countries, improving the accessibility of Chinese technology in resource scarce areas, striving to improve health inequality and contributing to global health. We have helped Convidecia® filling manufacturing line in Malaysia obtain GMP certification, and continue to expand the capacity building in developing countries and low-and middle-income regions.

Health Science Education: Leveraging our professional advantages, CanSinoBIO actively carries out characteristic public welfare activities with corporate characteristics. We adhere to the concept of “Innovation for a Safer World” and carry out health knowledge popularization.

Establish Halal product assurance system to guarantee the Halal products comply with the requirements: To meet the needs of different cultural and religious backgrounds, we have established a comprehensive Halal product assurance system to ensure that Halal products are produced consistently and sustainably, in strict compliance with Halal requirements. Our Halal vaccines will meet the needs of Muslim consumers and will earn the trust and recognition of a wide range of consumers, further underscoring our strong mission to provide innovative, high-quality, and affordable vaccines for the world.

Build Immune Barriers In The Whole World

Facing the widespread of COVID-19 in the world, CanSinoBIO has sent R&D teams to countries and regions that suffer the most, to guide local researchers to carry out the clinical trials on COVID-19 vaccines, combining the vaccine R&D technologies in China and local situations. Our efforts have obtained excellent fruits and effectively helped locals to fight against the COVID-19. We will keep cooperating with all partners to jointly help the fair distribution of COVID-19 vaccines in the world and to contribute to the improvement of the global public healthcare system.

Asia

Asia

Indonesia: Convidecia® adn Convidecia Air® were officially approved in Indonesia. Convidecia® passes Halal Decree. Convidecia Air® obtained an emergency use permit issued by BPOM; CanSinoBIO and the Indonesian Biopharmaceutical Company—Etana signed
a tripartite cooperation agreement on inhaled tuberculosis vaccine

Malaysia: Built vaccine manufacturing base to realize localized manufacturing. Convidecia® was used locally as a general-purpose booster, Convidecia Air® obtained a clinical trial permit in Malaysia, and CanSinoBIO carried out more in-depth vaccine cooperation with Malaysia on behalf of China, signing a share subscription agreement with Solution Group Berhad

Pakistan: Convidecia® obtained emergency use authorization, and vaccine manufacturing base was built to realize localized manufacturing

Kyrgyzstan: Convidecia® obtained emergency use authorization

United Arab Emirates: Convidecia® obtained emergency use authorization

Saudi Arabia: Signed cooperation framework agreement on innovative vaccine with Saudi Arabia’s pharmaceutical manufacturing company SPIMACO

Europe

Europe

Hungary: Obtained the EU GMP certificate for Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) and obtained the local emergency use authorization

Sweden: Signed product supply cooperation Asia framework agreement with AstraZeneca Sweden

Africa

Africa

Argentina: Convidecia® obtained emergency use authorization and was officially registered in Argentina, it was recommended as a heterologous booster

Chile: Convidecia® obtained emergency use authorization and was widely administered

Ecuador: Convidecia® obtained emergency use authorization

North America

North America

Canada: CanSinoBIO's recombinant shingles vaccine received the No-Objection Letter on Clinical Trials from the Public Health Agency of Canada, CanSinoBIO has launched Phase I clinical trial and the first trial patient case has been formally enrolled

Mexico: A vaccine manufacturing base was established to realize localized manufacturing

South America

South America

Argentina: Convidecia® obtained emergency use authorization and was officially registered in Argentina, it was recommended as a heterologous booster

Chile: Convidecia® obtained emergency use authorization and was widely administered

Ecuador: Convidecia® obtained emergency use authorization

美国: 康希诺生物股份公司美国分公司

天津: 康希诺生物股份公司

北京: 康希诺生物股份公司北京分公司

新加坡: 康希诺生物(新加坡)股份公司

Pharmacovigilance

CanSinoBIO complies with laws and regulations such as the Law of the PRC on Pharmaceutical Administration, the Law of the PRC on Vaccine Administration, the Administrative Measures for the Reporting and Monitoring of Adverse Drug Reactions, and the Pharmacovigilance Quality Management Regulation, and formulated internal pharmacovigilance system documents such as the Constitution of the Drug Safety Committee, the Pharmacovigilance Management System, the Regulation for Pharmacovigilance Management during Clinical Trials, we have established a full lifecycle pharmacovigilance management system covering non-clinical stage, clinical stage and post-marketing stage.